Revenue of ¥50 billion, operating profit of ¥5 billion, and ROE of 8.0% for the fiscal year ending September 2024
First written in FY2020. 2 of 5 entries say "Restated". Latest entry: FY2025-H1.
Fuji Pharma moved to the "Worse" side of this theme in 2025, 3 years after the typical company in this theme (2022).
The whole theme swung hardest in 2021: 5 of 21 companies on the "Worse" side.
4 other companies' latest entry also says "Reframed".
- FY2025-H1ReframedAnnual report
「The company formulated the "Long-Term Vision 2035" and is pursuing, as its medium-term management plan, four growth strategies over the next 5 years to achieve it: "expanding contributions to women's healthcare," "expanding contributions through the biosimilars business," "contributing earnings through the global CMO business," and "laying the groundwork for and identifying the next growth drivers." To strengthen the management platform supporting these strategies, it is also pursuing three initiatives: "strengthening human resources," "advancing organizational capabilities," and "promoting digitalization."」
In place of the former medium-term management plan's targets of ¥50 billion in revenue, ¥5 billion in operating profit and ROE of 8.0% for the fiscal year ending September 2024, the company has presented the Long-Term Vision 2035 and new growth strategies for the next 5 years. - FY2024-Q1Arrival of the final yearAnnual report
「As a midpoint, the company formulated a medium-term management plan with the fiscal year ending September 2024 as its final year. In this medium-term management plan, which has reached its final year, the theme is "Making Fuji Uniquely New,"」
Although the numerical targets for the fiscal year ending September 2024 are not reiterated in this filing, it states that the medium-term management plan reached its final year. This statement does not establish whether the targets were achieved. - FY2022RestatedAnnual report
「For the fiscal year ending September 2024, the final year of the medium-term management plan, we aim to achieve revenue of ¥50.0 billion, operating profit of ¥5.0 billion and return on equity (ROE) of 8.0%.」
It continues to set numerical targets of ¥50 billion in revenue, ¥5 billion in operating profit and ROE of 8.0% for the fiscal year ending September 2024. - FY2021RestatedAnnual report
「For the fiscal year ending September 2024, the final year of the medium-term management plan, we aim to achieve revenue of ¥50.0 billion, operating profit of ¥5.0 billion and return on equity (ROE) of 8.0%.」
It continues to set numerical targets of ¥50 billion in revenue, ¥5 billion in operating profit and ROE of 8.0% for the fiscal year ending September 2024. - FY2020First statedAnnual report
「For the fiscal year ending September 2024, the final year of the medium-term management plan, we aim to achieve revenue of ¥50.0 billion, operating profit of ¥5.0 billion and return on equity (ROE) of 8.0%.」
Toward the final year of the new medium-term management plan, "Making Fuji Uniquely New," it sets out revenue, operating profit and ROE targets as independent targets for the first time.